MAPS Just Partnered on Training. Here Is Who Else Decides Who Delivers Psychedelic Therapy
If psychedelic therapies reach the market, somebody has to train the people who deliver them. On October 5, MAPS and the International Alliance of Psychedelic Therapy Practitioners announced a partnership aimed at exactly that. The training landscape it enters has several moving parts and no single authority. That is the practical problem for any clinic planning to staff this work.
Hiring is the hardest line in a psychedelic service plan. The rest of the overhead is negotiable. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The announcement | MAPS and the Psychedelic Therapy Alliance will work together on education and standards |
| The scope | Training programs, clinical consultation, continuing education and scholarships |
| Who is behind it | Alliance founders include the clinicians who delivered the MDMA therapist training |
| Next step for practitioners | Alliance membership applications open this month |
| Why it matters now | FDA spent much of its September hearing on provider training and credentialing |
| The open question | States, manufacturers and professional bodies each define the role differently |
What Was Announced
MAPS is the nonprofit founded in 1986. The Alliance formed in 2023. Together they will work on professional education, clinical standards and workforce infrastructure, in the United States and abroad.
The stated scope covers training programs, clinical consultation and continuing education. It also includes scholarship and sponsored attendance meant to widen access to that training.
Betty Aldworth of MAPS said the Alliance brings together many of the clinicians and educators who shaped this therapeutic lineage. Sara Gael of the Alliance said the partnership helps ensure future training is informed by decades of clinical practice.
Practitioners who want in can start now. Alliance membership applications open this month.
The People Involved Are the Ones Who Did the Work
The Alliance’s named founding members include Annie Mithoefer and Michael Mithoefer, Bruce Poulter, Marcela Ot’alora G., Keren Tzarfaty, Ido Siemion and Ingrid Pacey.
That group trained and supervised the therapists who delivered MDMA-assisted therapy in the trials that brought this field to the FDA. No deeper bench of hands-on experience exists.
Whatever a future credential looks like, curricula built by the people who ran the sessions start from something real.
Why Training Became the Live Question
FDA devoted a large share of its September public hearing to provider training and credentialing. It was one of four topics the agency named, and we covered the day in our look at the label fight.
The reason is simple. These treatments are delivered, not dispensed. A label that defines who must be in the room decides the cost of every session.
Four Answers, None Final
States already credential facilitators. Oregon licenses them and funds the program through its own fees. That model is under strain, as we saw when the state withdrew a proposed fee increase. New Mexico is building its program now, and the clinician facing permit is still pending.
Manufacturers describe their own staffing models. Compass has said its treatment slots into existing interventional psychiatry centers. The model is a multidisciplinary team with a single prescriber on site, which we covered in psilocybin launching through Spravato clinics.
Trial protocols set a different bar. The Israeli MDMA program pairs two therapists with each patient for every session. We examined that in our piece on what the protocol asks of a clinic.
Professional bodies are building the training itself. That is where this partnership sits, alongside university programs and private institutes already offering certificates.
What a Clinic Owner Can Do With This
Hiring decisions made now will be judged by rules written later. That argues for flexible choices rather than a bet on one credential.
Clinicians who already hold a license to practice are the safest foundation. Psychiatrists, nurse practitioners, physician assistants, CRNAs and licensed therapists carry credentials that no future framework will discard.
Training on top of that license is additive. A staff member who completes a respected program is better prepared either way, and the cost of that training is modest next to the cost of rebuilding a team.
It is also worth tracking which programs the people writing the rules take seriously. Lineage matters in a field this young, and this partnership consolidates a good deal of it.
The Bottom Line
Approval decides whether these treatments exist. Training decides whether anyone can deliver them well.
A partnership between the field’s largest nonprofit and the clinicians who built its therapy model is a sensible place for that work to happen. The details will matter, and they are still to come.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not legal or medical advice. Psilocybin and MDMA assisted therapies are not approved by the FDA.
